2013 Q4 Form 10-K Financial Statement
#000104746914000693 Filed on February 07, 2014
Income Statement
| Concept | 2013 Q4 | 2013 Q3 | 2013 Q2 |
|---|---|---|---|
| Revenue | $5.031M | $4.932M | $9.663M |
| YoY Change | -81.35% | -94.88% | -33.83% |
| Cost Of Revenue | $500.0K | $2.021M | $3.418M |
| YoY Change | -50.0% | ||
| Gross Profit | $4.500M | $2.911M | $6.245M |
| YoY Change | -82.69% | -96.98% | -57.23% |
| Gross Profit Margin | 89.45% | 59.02% | 64.63% |
| Selling, General & Admin | $28.70M | $30.26M | $30.87M |
| YoY Change | -31.01% | 32.47% | 53.59% |
| % of Gross Profit | 637.78% | 1039.64% | 494.32% |
| Research & Development | $22.50M | $23.02M | $24.09M |
| YoY Change | -20.49% | -1.86% | -25.27% |
| % of Gross Profit | 500.0% | 790.66% | 385.8% |
| Depreciation & Amortization | $3.100M | $3.000M | $2.800M |
| YoY Change | 10.71% | 0.0% | 0.0% |
| % of Gross Profit | 68.89% | 103.06% | 44.84% |
| Operating Expenses | $51.30M | $53.28M | $54.96M |
| YoY Change | -26.61% | 9.17% | 5.02% |
| Operating Profit | -$46.80M | -$56.55M | -$59.88M |
| YoY Change | 6.61% | -218.78% | 46.64% |
| Interest Expense | -$5.200M | $5.265M | $5.318M |
| YoY Change | 37507.14% | 40807.69% | |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$5.248M | -$5.224M | -$5.269M |
| YoY Change | -11762.22% | -19448.15% | -17096.77% |
| Pretax Income | -$52.00M | -$61.80M | -$65.10M |
| YoY Change | 18.45% | -229.74% | 59.56% |
| Income Tax | $0.00 | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | -$52.00M | -$61.78M | -$65.10M |
| YoY Change | 18.45% | -229.68% | 59.56% |
| Net Earnings / Revenue | -1033.59% | -1252.53% | -673.7% |
| Basic Earnings Per Share | -$0.43 | -$0.51 | -$0.57 |
| Diluted Earnings Per Share | -$0.43 | -$0.51 | -$0.57 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 120.8M shares | ||
| Diluted Shares Outstanding | 120.8M shares |
Balance Sheet
| Concept | 2013 Q4 | 2013 Q3 | 2013 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $197.6M | $242.4M | $300.5M |
| YoY Change | 17.48% | 25.4% | 90.55% |
| Cash & Equivalents | $75.49M | $144.5M | $219.5M |
| Short-Term Investments | $122.1M | $97.90M | $81.10M |
| Other Short-Term Assets | $6.200M | $9.800M | $9.600M |
| YoY Change | -22.5% | 24.05% | 60.0% |
| Inventory | $22.15M | $20.56M | $20.38M |
| Prepaid Expenses | |||
| Receivables | $513.0K | $125.0K | $5.300M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $229.1M | $275.8M | $335.8M |
| YoY Change | 24.23% | 36.31% | 102.16% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $37.38M | $37.23M | $35.01M |
| YoY Change | -0.43% | 2.09% | 0.32% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $4.311M | $4.639M | $5.091M |
| YoY Change | 1423.32% | 8490.74% | -33.88% |
| Total Long-Term Assets | $49.83M | $50.02M | $48.25M |
| YoY Change | 9.6% | 13.23% | 13.27% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $229.1M | $275.8M | $335.8M |
| Total Long-Term Assets | $49.83M | $50.02M | $48.25M |
| Total Assets | $279.0M | $325.8M | $384.0M |
| YoY Change | 21.34% | 32.18% | 84.01% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $10.14M | $2.436M | $6.569M |
| YoY Change | -28.68% | -8.14% | -38.03% |
| Accrued Expenses | $18.44M | $18.80M | $17.12M |
| YoY Change | -12.91% | 12.65% | -14.81% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $1.100M | $1.100M | $200.0K |
| YoY Change | 266.67% | 266.67% | -33.33% |
| Total Short-Term Liabilities | $41.04M | $39.70M | $43.97M |
| YoY Change | -25.3% | 11.59% | -10.46% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $177.8M | $178.1M | $174.8M |
| YoY Change | 59166.67% | 44425.0% | 43600.0% |
| Other Long-Term Liabilities | $1.653M | $1.653M | $1.653M |
| YoY Change | 66.63% | -94.2% | -94.56% |
| Total Long-Term Liabilities | $1.653M | $1.653M | $1.653M |
| YoY Change | 66.63% | -94.28% | -94.63% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $41.04M | $39.70M | $43.97M |
| Total Long-Term Liabilities | $1.653M | $1.653M | $1.653M |
| Total Liabilities | $42.69M | $41.35M | $45.62M |
| YoY Change | -23.67% | -35.79% | -42.9% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$777.8M | -$725.8M | -$664.1M |
| YoY Change | 54.02% | 57.39% | |
| Common Stock | $815.9M | $809.9M | $803.4M |
| YoY Change | 25.73% | 25.93% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $38.23M | $84.21M | $139.4M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $279.0M | $325.8M | $384.0M |
| YoY Change | 21.34% | 32.18% | 84.01% |
Cashflow Statement
| Concept | 2013 Q4 | 2013 Q3 | 2013 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$52.00M | -$61.78M | -$65.10M |
| YoY Change | 18.45% | -229.68% | 59.56% |
| Depreciation, Depletion And Amortization | $3.100M | $3.000M | $2.800M |
| YoY Change | 10.71% | 0.0% | 0.0% |
| Cash From Operating Activities | -$42.10M | -$58.00M | -$80.10M |
| YoY Change | 87.95% | -248.72% | 85.85% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$3.700M | -$1.000M | -$2.000M |
| YoY Change | 8.82% | -72.22% | -16.67% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$24.30M | -$17.10M | $55.20M |
| YoY Change | -168.07% | -710.71% | -18500.0% |
| Cash From Investing Activities | -$28.00M | -$18.10M | $53.20M |
| YoY Change | -186.96% | 2916.67% | -2000.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 1.200M | 1.000M | 141.1M |
| YoY Change | 9.09% | 100.0% | 10753.85% |
| NET CHANGE | |||
| Cash From Operating Activities | -42.10M | -58.00M | -80.10M |
| Cash From Investing Activities | -28.00M | -18.10M | 53.20M |
| Cash From Financing Activities | 1.200M | 1.000M | 141.1M |
| Net Change In Cash | -68.90M | -75.10M | 114.2M |
| YoY Change | -732.11% | -293.06% | -356.05% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$42.10M | -$58.00M | -$80.10M |
| Capital Expenditures | -$3.700M | -$1.000M | -$2.000M |
| Free Cash Flow | -$38.40M | -$57.00M | -$78.10M |
| YoY Change | 102.11% | -233.8% | 91.89% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
815930000 | USD |
| CY2013 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Use of Estimates</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. requires the Company's management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to revenue recognition, available-for-sale securities, inventory valuation and related reserves, impairment of long-lived assets, balance sheet classification of notes payable, income taxes including the valuation allowance for deferred tax assets, research and development expense, contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</font></p> </div> | |
| CY2013 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Concentrations of Credit Risk</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, restricted cash, available-for-sale securities, and accounts receivable. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company's available-for-sale investments primarily consist of U.S. Treasury securities and certain U.S. government sponsored securities and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy which limits the amounts the Company may invest in any one type of investment, and requires all investments held by the Company to be at least A+ rated, thereby reducing credit risk exposure.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        Accounts receivable, including related party accounts receivable, primarily consist of amounts due under the collaboration agreement with Forest and license agreement with Astellas (Note 4) for which the Company does not obtain collateral. Accounts receivable or payable to or from Forest and Almirall are presented as related party transactions on the consolidated balance sheets as both entities own common stock of the Company.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The percentages of revenue recognized from significant customers of the Company in the years ended December 31, 2013, 2012 and 2011 as well as the account receivable balances, net of any payables due, at December 31, 2013 and 2012 are included in the following table:</font></p> <div style="POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-LEFT: 0pt; WIDTH: 70%; PADDING-RIGHT: 0pt; MARGIN-LEFT: 15%; PADDING-TOP: 0pt;"> <p style="FONT-FAMILY: times;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p> <!-- User-specified TAGGED TABLE --> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="100%" style="text-align:left;"> <tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET --> <td style="FONT-FAMILY: times;" align="left"></td> <td style="FONT-FAMILY: times;" width="12"></td> <td style="FONT-FAMILY: times;" width="7" align="right"></td> <td style="FONT-FAMILY: times;" width="44"></td> <td style="FONT-FAMILY: times;" width="12"></td> <td style="FONT-FAMILY: times;" width="7" align="right"></td> <td style="FONT-FAMILY: times;" width="44"></td> <td style="FONT-FAMILY: times;" width="12"></td> <td style="FONT-FAMILY: times;" width="7" align="right"></td> <td style="FONT-FAMILY: times;" width="44"></td> <td style="FONT-FAMILY: times;" width="12"></td> <td style="FONT-FAMILY: times;" width="7" align="right"></td> <td style="FONT-FAMILY: times;" width="44"></td> <td style="FONT-FAMILY: times;" width="12"></td> <td style="FONT-FAMILY: times;" width="7" align="right"></td> <td style="FONT-FAMILY: times;" width="44"></td> <td style="FONT-FAMILY: times;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr> <tr style="padding:0;" valign="bottom"> <th style="FONT-FAMILY: times;" align="left"><font size="2"> </font><br /></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th> <th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times;" colspan="5" align="center"><font size="1"><b>Accounts Receivable</b></font></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th> <th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times;" colspan="8" align="center"><font size="1"><b>Revenue</b></font></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th></tr> <tr style="padding:0;" valign="bottom"> <th style="FONT-FAMILY: times;" align="left"><font size="1"> </font><br /></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th> <th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times;" colspan="5" align="center"><font size="1"><b>December 31,</b></font></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th> <th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times;" colspan="8" align="center"><font size="1"><b>Years Ended December 31,</b></font></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th></tr> <tr style="padding:0;" valign="bottom"> <th style="FONT-FAMILY: times;" align="left"><font size="1"> </font><br /></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th> <th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times;" colspan="2" align="center"><font size="1"><b>2013</b></font></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th> <th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times;" colspan="2" align="center"><font size="1"><b>2012</b></font></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th> <th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times;" colspan="2" align="center"><font size="1"><b>2013</b></font></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th> <th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times;" colspan="2" align="center"><font size="1"><b>2012</b></font></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th> <th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times;" colspan="2" align="center"><font size="1"><b>2011</b></font></th> <th style="FONT-FAMILY: times;"><font size="1"> </font></th></tr> <tr style="padding:0;" valign="top" bgcolor="#CCEEFF"> <td style="FONT-FAMILY: times;" valign="bottom"> <p style="TEXT-INDENT: -10pt; FONT-FAMILY: times; MARGIN-LEFT: 10pt;"><font size="2"><b>Collaborative Partner:</b></font></p></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td></tr> <tr style="padding:0;" valign="top" bgcolor="white"> <td style="FONT-FAMILY: times;" valign="bottom"> <p style="TEXT-INDENT: -10pt; FONT-FAMILY: times; MARGIN-LEFT: 10pt;"><font size="2">Forest</font></p></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">84</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">—</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">13</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">67</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">64</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td></tr> <tr style="padding:0;" valign="top" bgcolor="#CCEEFF"> <td style="FONT-FAMILY: times;" valign="bottom"> <p style="TEXT-INDENT: -10pt; FONT-FAMILY: times; MARGIN-LEFT: 10pt;"><font size="2">Almirall</font></p></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">—</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">69</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">57</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">14</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">31</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td></tr> <tr style="padding:0;" valign="top" bgcolor="white"> <td style="FONT-FAMILY: times;" valign="bottom"> <p style="TEXT-INDENT: -10pt; FONT-FAMILY: times; MARGIN-LEFT: 10pt;"><font size="2">Astellas</font></p></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">16</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">31</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">25</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">3</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">5</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td></tr> <tr style="padding:0;" valign="top" bgcolor="#CCEEFF"> <td style="FONT-FAMILY: times;" valign="bottom"> <p style="TEXT-INDENT: -10pt; FONT-FAMILY: times; MARGIN-LEFT: 10pt;"><font size="2">AstraZeneca</font></p></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">—</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">—</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">5</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">16</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2"> </font></td> <td style="FONT-FAMILY: times;" valign="bottom" align="right"><font size="2">—</font></td> <td style="FONT-FAMILY: times;" valign="bottom"><font size="2">%</font></td></tr></table></div> <!-- end of user-specified TAGGED TABLE --></div> <p style="FONT-FAMILY: times;"><font size="2">        As of December 31, 2013, the Company was in a net payable position with AstraZeneca; as such, there was no accounts receivable due from AstraZeneca as of December 31, 2013. As of December 31, 2012, the Company was in a net payable position with Forest; as such, there was no accounts receivable due from Forest as of December 31, 2012.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        For the years ended December 31, 2013, 2012 and 2011, no additional customers accounted for more than 10% of the Company's revenue.</font></p> </div> | |
| CY2013Q4 | irwd |
Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions For More Than Twelve Months
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsForMoreThanTwelveMonths
|
0 | item |
| CY2012Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
3000000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
38700000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
122110000 | USD |
| CY2013 | us-gaap |
Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
|
6000 | USD |
| CY2013 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | segment |
| CY2013Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
67300000 | USD |
| CY2012Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
113900000 | USD |
| CY2013 | irwd |
Available For Sale Threshold Months
AvailableForSaleThresholdMonths
|
P3M | |
| CY2012 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
19620000 | shares |
| CY2011 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
16585000 | shares |
| CY2013 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
20928000 | shares |
| CY2013Q4 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | USD |
| CY2012Q4 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | USD |
| CY2012Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
31523000 | USD |
| CY2012 | us-gaap |
Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
|
6000 | USD |
| CY2012 | us-gaap |
Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
|
1000 | USD |
| CY2012Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
31528000 | USD |
| CY2013 | irwd |
Available For Sale Securities Debt Maturity Period Range High
AvailableForSaleSecuritiesDebtMaturityPeriodRangeHigh
|
P1Y | |
| CY2013Q4 | us-gaap |
Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
|
12 | item |
| CY2012Q4 | us-gaap |
Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
|
3 | item |
| CY2012Q4 | irwd |
Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions For More Than Twelve Months
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsForMoreThanTwelveMonths
|
0 | item |
| CY2013Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
122112000 | USD |
| CY2013 | us-gaap |
Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
|
4000 | USD |
| CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
22145000 | USD |
| CY2012Q4 | us-gaap |
Inventory Net
InventoryNet
|
6699000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
79065000 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
74517000 | USD |
| CY2013Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
41689000 | USD |
| CY2012Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
36980000 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
37537000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
37376000 | USD |
| CY2013Q4 | us-gaap |
Capital Leased Assets Gross
CapitalLeasedAssetsGross
|
5500000 | USD |
| CY2012Q4 | us-gaap |
Capital Leased Assets Gross
CapitalLeasedAssetsGross
|
1400000 | USD |
| CY2013Q4 | us-gaap |
Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
|
1200000 | USD |
| CY2012Q4 | us-gaap |
Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
|
900000 | USD |
| CY2013 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
11729000 | USD |
| CY2012 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
11325000 | USD |
| CY2011 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
9999000 | USD |
| CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
14594000 | USD |
| CY2012Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1031000 | USD |
| CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5546000 | USD |
| CY2012Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
21171000 | USD |
| CY2013Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
13784000 | USD |
| CY2013Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
531000 | USD |
| CY2013Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
856000 | USD |
| CY2013Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
18438000 | USD |
| CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3267000 | USD |
| CY2011 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
456000 | USD |
| CY2011 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
900000 | USD |
| CY2013 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-20810000 | USD |
| CY2012 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
138000 | USD |
| CY2011 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1293000 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-272812000 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-72624000 | USD |
| CY2011 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-64849000 | USD |
| CY2011 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
3000 | USD |
| CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
184440000 | USD |
| CY2012Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
7647000 | USD |
| CY2012Q4 | us-gaap |
Assets
Assets
|
229907000 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
14217000 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
7509000 | USD |
| CY2012Q4 | irwd |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
5664000 | USD |
| CY2012Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
261000 | USD |
| CY2012Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
2735000 | USD |
| CY2012Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
3381000 | USD |
| CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
54938000 | USD |
| CY2013Q4 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
174672000 | USD |
| CY2012Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
308000 | USD |
| CY2012Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
11593000 | USD |
| CY2012Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
18024000 | USD |
| CY2013Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
2790000 | USD |
| CY2012Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
992000 | USD |
| CY2013Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2012Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
648955000 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-777828000 | USD |
| CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-505016000 | USD |
| CY2013Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
2000 | USD |
| CY2012Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
5000 | USD |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
38225000 | USD |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
144052000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
41040000 | USD |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
229128000 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
278962000 | USD |
| CY2012Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2013Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
75000000 | shares |
| CY2013Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
75000000 | shares |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2013Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2013Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2013 | us-gaap |
Revenues
Revenues
|
22881000 | USD |
| CY2013 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
7203000 | USD |
| CY2012 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
965000 | USD |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
102378000 | USD |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
113474000 | USD |
| CY2011 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
86093000 | USD |
| CY2013 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
123228000 | USD |
| CY2012 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
92538000 | USD |
| CY2011 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
45920000 | USD |
| CY2013 | irwd |
Collaboration Expense
CollaborationExpense
|
42074000 | USD |
| CY2012 | irwd |
Collaboration Expense
CollaborationExpense
|
16030000 | USD |
| CY2013 | us-gaap |
Interest Expense
InterestExpense
|
21002000 | USD |
| CY2012 | us-gaap |
Interest Expense
InterestExpense
|
59000 | USD |
| CY2011 | us-gaap |
Interest Expense
InterestExpense
|
63000 | USD |
| CY2013 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
192000 | USD |
| CY2012 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
197000 | USD |
| CY2013 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
274883000 | USD |
| CY2012 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
223007000 | USD |
| CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.35 | |
| CY2013 | dei |
Entity Registrant Name
EntityRegistrantName
|
IRONWOOD PHARMACEUTICALS INC | |
| CY2011 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
5000 | USD |
| CY2012 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1000 | USD |
| CY2011 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
5000 | USD |
| CY2012 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-72625000 | USD |
| CY2011 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-64847000 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-3000 | USD |
| CY2013 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-272815000 | USD |
| CY2013 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-610000 | USD |
| CY2012 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-20000 | USD |
| CY2011 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-7000 | USD |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
19829000 | USD |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
17573000 | USD |
| CY2011 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11732000 | USD |
| CY2013 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-1254000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
1726000 | USD |
| CY2011 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
132013000 | USD |
| CY2011 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.65 | |
| CY2012 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-1157000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
835000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-2243000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
500000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-2833000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
52000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
5127000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-2421000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
11915000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
6699000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-116000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-136000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-11724000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
24241000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
5086000 | USD |
| CY2013 | irwd |
Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
|
-2252000 | USD |
| CY2012 | irwd |
Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
|
-1346000 | USD |
| CY2011 | irwd |
Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
|
-1130000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
287943000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
96709000 | USD |
| CY2011 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
97511000 | USD |
| CY2013 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
196102000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
140757000 | USD |
| CY2011 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
222254000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
9592000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
13979000 | USD |
| CY2011 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
9682000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
9000 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
137766000 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
85228000 | USD |
| CY2013 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
175000000 | USD |
| CY2013 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
7717000 | USD |
| CY2013 | irwd |
Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock
ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock
|
9297000 | USD |
| CY2012 | irwd |
Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock
ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock
|
4020000 | USD |
| CY2011 | irwd |
Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock
ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock
|
3393000 | USD |
| CY2013 | us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
768000 | USD |
| CY2012 | us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
275000 | USD |
| CY2011 | us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
260000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
49418000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
42961000 | USD |
| CY2012 | us-gaap |
Interest Paid
InterestPaid
|
55000 | USD |
| CY2011 | us-gaap |
Interest Paid
InterestPaid
|
64000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-4915000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-36016000 | USD |
| CY2011 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
4000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
313578000 | USD |
| CY2011 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
3000 | USD |
| CY2012 | us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
247000 | USD |
| CY2011 | us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
325000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-45012000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-61210000 | USD |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
87282000 | USD |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
44321000 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
109856000 | USD |
| CY2010Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
159551000 | USD |
| CY2012 | irwd |
Stock Issued During Period Value Stock Options Exercised And Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndValueEmployeeStockPurchasePlan
|
4020000 | USD |
| CY2011 | irwd |
Stock Issued During Period Value Stock Options Exercised And Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndValueEmployeeStockPurchasePlan
|
3393000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-101433000 | USD |
| CY2012 | irwd |
Stock Issued During Period Value Stock Award
StockIssuedDuringPeriodValueStockAward
|
30000 | USD |
| CY2011 | irwd |
Stock Issued During Period Value Stock Award
StockIssuedDuringPeriodValueStockAward
|
30000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
85228000 | USD |
| CY2012 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
|
60000 | USD |
| CY2011 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
|
152000 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
17483000 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
11550000 | USD |
| CY2012 | irwd |
Adjustment To Additional Paid In Capital Restricted Stock Subject To Repurchase
AdjustmentToAdditionalPaidInCapitalRestrictedStockSubjectToRepurchase
|
-7000 | USD |
| CY2012 | irwd |
Adjustment To Additional Paid In Capital Vesting Of Restricted Stock No Longer Subject To Repurchase
AdjustmentToAdditionalPaidInCapitalVestingOfRestrictedStockNoLongerSubjectToRepurchase
|
7000 | USD |
| CY2011 | irwd |
Adjustment To Additional Paid In Capital Vesting Of Restricted Stock No Longer Subject To Repurchase
AdjustmentToAdditionalPaidInCapitalVestingOfRestrictedStockNoLongerSubjectToRepurchase
|
27000 | USD |
| CY2012 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-1000 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
5900000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
7900000 | USD |
| CY2013 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001446847 | |
| CY2013 | dei |
Document Type
DocumentType
|
10-K | |
| CY2013 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-12-31 | |
| CY2013 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2013 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2013 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
Yes | |
| CY2013 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2013 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2013 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
| CY2013 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>1. Nature of Business</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        Ironwood Pharmaceuticals, Inc. (the "Company") is an entrepreneurial pharmaceutical company focused on creating medicines that make a difference for patients, building value to earn the continued support of its fellow shareholders, and empowering its team to passionately pursue excellence. The Company's core strategy is to establish a leading gastrointestinal ("GI") therapeutics company, leveraging its development and commercial capabilities in addressing GI disorders as well as its pharmacologic expertise in guanylate cyclase ("GC") pathways.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company's lead product, linaclotide, is being marketed in the United States ("U.S.") under the trademarked name of LINZESS<sup>®</sup>. In August 2012, the United States Food and Drug Administration ("FDA") approved LINZESS as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation ("IBS-C") or chronic idiopathic constipation ("CIC"). LINZESS is the first and, to date, only FDA-approved guanylate cyclase type-C ("GC-C") agonist. The Company and its collaboration partner, Forest Laboratories, Inc. ("Forest"), began commercializing LINZESS in December 2012.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        In November 2012, the European Commission granted marketing authorization to linaclotide (CONSTELLA<sup>®</sup>) for the symptomatic treatment of moderate to severe IBS-C in adults. CONSTELLA is the first and only drug approved in the European Union ("E.U.") for IBS-C. The Company's European partner, Almirall, S.A. ("Almirall"), has exclusive marketing rights for CONSTELLA in Europe (including the Commonwealth of Independent States and Turkey). Currently, CONSTELLA is commercially available in certain European countries, including the United Kingdom and Germany.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        In December 2013, the Health Canada granted approval of CONSTELLA as a once-daily, first-in-class treatment for adult women and men suffering from IBS-C or CIC. Forest has exclusive rights to develop and commercialize linaclotide in Canada.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        Astellas Pharma Inc. ("Astellas"), the Company's partner in Japan, is developing linaclotide for the treatment of patients with IBS-C in its territory. Astellas recently completed a double-blind, placebo-controlled, dose-ranging Phase II clinical trial of linaclotide in adult patients with IBS-C. In February 2014, the Company received preliminary top level data for the Phase II trial from Astellas indicating that, while all linaclotide dose groups showed numerically higher responder rates in the primary endpoint than placebo, the responder rates were not statistically significant compared to placebo in this study. Linaclotide was well tolerated in all dose groups in this study. Data analysis is still ongoing at Astellas to determine next steps.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        In October 2012, the Company entered into a collaboration agreement with AstraZeneca AB ("AstraZeneca") to co-develop and co-commercialize linaclotide in China, Hong Kong and Macau, with AstraZeneca having primary responsibility for the local operational execution. In the third quarter of 2013, the Company and AstraZeneca initiated a double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with IBS-C.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company continues to assess alternatives to bring linaclotide to IBS-C and CIC sufferers in the parts of the world outside of its partnered territories.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company is also exploring development opportunities to enhance the clinical profile of LINZESS by seeking to expand its utility in its indicated populations, as well as studying linaclotide in additional indications and populations, new formulations and in combination with other products to assess its potential to treat various GI conditions. In addition to linaclotide-based opportunities, the Company is advancing multiple GI development programs as well as further leveraging its GC expertise to advance a second GC program targeting soluble guanylate cyclase, a validated mechanism with the potential for broad therapeutic utility and multiple opportunities for product development.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company was incorporated in Delaware on January 5, 1998 as Microbia, Inc. On April 7, 2008, the Company changed its name to Ironwood Pharmaceuticals, Inc. To date, the Company has dedicated substantially all of its activities to the research, development and commercialization of linaclotide, the Company's lead product and product candidate, as well as research and development of other product candidates. The Company has incurred significant operating losses since its inception in 1998. As of December 31, 2013, the Company had an accumulated deficit of $777.8 million.</font></p> </div> | |
| CY2013Q4 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
122112000 | USD |
| CY2013Q4 | irwd |
Number Of Series Of Common Stock
NumberOfSeriesOfCommonStock
|
2 | item |
| CY2013Q4 | irwd |
Class Of Warrant Or Right Minimum Percentage Of Beneficial Ownership In Common Stock
ClassOfWarrantOrRightMinimumPercentageOfBeneficialOwnershipInCommonStock
|
0.30 | pure |
| CY2013 | irwd |
Common Stock Conversion Ratio
CommonStockConversionRatio
|
1 | pure |
| CY2013Q4 | irwd |
Threshold Number Of Class B Common Stock Shares Outstanding Used To Determine Date Of Conversion
ThresholdNumberOfClassBCommonStockSharesOutstandingUsedToDetermineDateOfConversion
|
19561556 | shares |
| CY2013Q4 | irwd |
Percentage Of Number Of Class B Common Stock Shares Outstanding Immediately Following Initial Public Offering Used To Determine Date Of Conversion
PercentageOfNumberOfClassBCommonStockSharesOutstandingImmediatelyFollowingInitialPublicOfferingUsedToDetermineDateOfConversion
|
0.25 | pure |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
14152000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
15255000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
15778000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
604000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
58861000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
13072000 | USD |
| CY2013Q4 | us-gaap |
Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
|
1434000 | USD |
| CY2013Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
|
1265000 | USD |
| CY2013Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
|
2157000 | USD |
| CY2013Q4 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
4856000 | USD |
| CY2013Q4 | us-gaap |
Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
|
-583000 | USD |
| CY2013Q4 | us-gaap |
Capital Lease Obligations
CapitalLeaseObligations
|
4273000 | USD |
| CY2013Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
1139000 | USD |
| CY2013Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
3134000 | USD |
| CY2013Q4 | irwd |
Long Term Purchase Commitment Amount First Full Fiscal Year
LongTermPurchaseCommitmentAmountFirstFullFiscalYear
|
8700000 | USD |
| CY2013Q4 | irwd |
Long Term Purchase Commitment Amount Second Full Fiscal Year
LongTermPurchaseCommitmentAmountSecondFullFiscalYear
|
5900000 | USD |
| CY2013Q4 | irwd |
Long Term Purchase Commitment Amount Third Full Fiscal Year
LongTermPurchaseCommitmentAmountThirdFullFiscalYear
|
7900000 | USD |
| CY2013Q4 | irwd |
Long Term Purchase Commitment Amount Fourth Full Fiscal Year
LongTermPurchaseCommitmentAmountFourthFullFiscalYear
|
7900000 | USD |
| CY2013Q4 | irwd |
Long Term Purchase Commitment Amount Fifth Full Fiscal Year
LongTermPurchaseCommitmentAmountFifthFullFiscalYear
|
2500000 | USD |
| CY2013 | irwd |
Defined Contribution Plan Employer Matching Contribution Employee Contribution Percent
DefinedContributionPlanEmployerMatchingContributionEmployeeContributionPercent
|
0.75 | pure |
| CY2013 | us-gaap |
Interest Paid
InterestPaid
|
18428000 | USD |
| CY2013 | us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
4472000 | USD |
| CY2013 | irwd |
Defined Contribution Plan Employer Matching Contribution Employee Contribution Maximum
DefinedContributionPlanEmployerMatchingContributionEmployeeContributionMaximum
|
6000 | USD |
| CY2013Q2 | dei |
Entity Public Float
EntityPublicFloat
|
1108219339 | USD |
| CY2013 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | |
| CY2013 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2011 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
3000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-92756000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
1413000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-13684000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
3830000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
|
5089000 | USD |
| CY2013 | irwd |
Income Tax Reconciliation Change In Enacted State And Local Tax Rates
IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates
|
1057000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
105186000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
43000 | USD |
| CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
115852000 | shares |
| CY2012 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-24692000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
288000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-3835000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
3531000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
|
10420000 | USD |
| CY2012 | irwd |
Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits
IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits
|
564000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
34577000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-13000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-22050000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
245000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-3531000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
2104000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
|
-509000 | USD |
| CY2011 | irwd |
Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits
IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits
|
803000 | USD |
| CY2011 | irwd |
Income Tax Reconciliation Change In Enacted State And Local Tax Rates
IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates
|
98000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
20955000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
870000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
231660000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
29533000 | USD |
| CY2013Q4 | irwd |
Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
|
11939000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
6433000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
29223000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
308788000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
308788000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
127928000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
24444000 | USD |
| CY2012Q4 | irwd |
Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
|
17305000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
8300000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
25036000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
203013000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
203013000 | USD |
| CY2012 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
34800000 | USD |
| CY2013 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
105800000 | USD |
| CY2013Q4 | irwd |
Excess Tax Benefit From Share Based Compensation Not Recognized
ExcessTaxBenefitFromShareBasedCompensationNotRecognized
|
37300000 | USD |
| CY2013 | irwd |
Minimum Period For Which Jobs Must Be Maintained
MinimumPeriodForWhichJobsMustBeMaintained
|
P5Y | |
| CY2013Q1 | us-gaap |
Revenues
Revenues
|
3255000 | USD |
| CY2013Q2 | us-gaap |
Revenues
Revenues
|
9663000 | USD |
| CY2013Q3 | us-gaap |
Revenues
Revenues
|
4932000 | USD |
| CY2013Q4 | us-gaap |
Revenues
Revenues
|
5031000 | USD |
| CY2012 | us-gaap |
Revenues
Revenues
|
150245000 | USD |
| CY2013Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
92088000 | USD |
| CY2013Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
69543000 | USD |
| CY2013Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
61483000 | USD |
| CY2013Q4 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
51769000 | USD |
| CY2013Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-5069000 | USD |
| CY2013Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-5269000 | USD |
| CY2013Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-5224000 | USD |
| CY2013Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-5248000 | USD |
| CY2013Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-93902000 | USD |
| CY2013Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-65149000 | USD |
| CY2013Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-61775000 | USD |
| CY2013Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-51986000 | USD |
| CY2013 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-272812000 | USD |
| CY2012Q1 | us-gaap |
Revenues
Revenues
|
12248000 | USD |
| CY2012Q2 | us-gaap |
Revenues
Revenues
|
14604000 | USD |
| CY2012Q3 | us-gaap |
Revenues
Revenues
|
96413000 | USD |
| CY2012Q4 | us-gaap |
Revenues
Revenues
|
26980000 | USD |
| CY2011 | us-gaap |
Revenues
Revenues
|
65871000 | USD |
| CY2012Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
47884000 | USD |
| CY2012Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
55438000 | USD |
| CY2012Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
48805000 | USD |
| CY2012Q4 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
70880000 | USD |
| CY2012Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
35000 | USD |
| CY2012Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
31000 | USD |
| CY2012Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
27000 | USD |
| CY2012Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
45000 | USD |
| CY2012Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-35601000 | USD |
| CY2012Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-40803000 | USD |
| CY2012Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
47635000 | USD |
| CY2012Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-43855000 | USD |
| CY2012 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-72624000 | USD |
| CY2012Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.34 | |
| CY2012Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.38 | |
| CY2012Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.44 | |
| CY2012Q4 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.41 | |
| CY2012 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.68 | |
| CY2012Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.34 | |
| CY2012Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.38 | |
| CY2012Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.42 | |
| CY2012Q4 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.41 | |
| CY2012 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.68 | |
| CY2013Q1 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.11 | pure |
| CY2012 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
106403000 | shares |
| CY2012 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
89800000 | USD |
| CY2011 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
212300000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
51000000 | USD |
| CY2011 | us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
10000000 | USD |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
19829000 | USD |
| CY2012 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
17573000 | USD |
| CY2011 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11732000 | USD |
| CY2011 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
99875000 | shares |
| CY2013 | us-gaap |
Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
|
17500000 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
136700000 | USD |
| CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.51 | |
| CY2013Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.57 | |
| CY2013Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.87 | |
| CY2013Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.51 | |
| CY2013Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.57 | |
| CY2013Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.87 | |
| CY2013 | irwd |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans Under Which Awards Currently Being Made
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansUnderWhichAwardsCurrentlyBeingMade
|
2 | item |
| CY2013 | irwd |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans Under Which Awards Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansUnderWhichAwardsOutstanding
|
2 | item |
| CY2013 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.35 | |
| CY2013 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.35 | |
| CY2013 | irwd |
Stock Issued During Period Value Stock Options Exercised And Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndValueEmployeeStockPurchasePlan
|
9297000 | USD |
| CY2013 | irwd |
Stock Issued During Period Value Stock Award
StockIssuedDuringPeriodValueStockAward
|
28000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
19624000 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-3000 | USD |
| CY2013 | us-gaap |
Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
|
0 | USD |
| CY2012 | us-gaap |
Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
|
0 | USD |
| CY2011 | us-gaap |
Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
|
0 | USD |
| CY2013 | us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
0 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
278962000 | USD |
| CY2013Q4 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.43 | |
| CY2011 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-2234000 | USD |
| CY2013Q4 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.43 | |
| CY2013Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
513000 | USD |
| CY2013Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
2700000 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
6168000 | USD |
| CY2013Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
8147000 | USD |
| CY2013Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
4311000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
10139000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
48000 | USD |
| CY2013Q4 | irwd |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
3412000 | USD |
| CY2013Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
8822000 | USD |
| CY2013Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
5074000 | USD |
| CY2013Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
11416000 | USD |
| CY2013Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1653000 | USD |
| CY2012Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
229907000 | USD |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-252002000 | USD |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-72762000 | USD |
| CY2011 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-66142000 | USD |
| CY2013 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
1719000 | USD |
| CY2013 | irwd |
Increase Decrease In Deferred Rent Payables
IncreaseDecreaseInDeferredRentPayables
|
-2716000 | USD |
| CY2012 | irwd |
Increase Decrease In Deferred Rent Payables
IncreaseDecreaseInDeferredRentPayables
|
-2149000 | USD |
| CY2011 | irwd |
Increase Decrease In Deferred Rent Payables
IncreaseDecreaseInDeferredRentPayables
|
-934000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
992000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-273355000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-69633000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-75237000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
30078000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
115065000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
88973000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3133000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
137766000 | USD |
| CY2013 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
|
272000 | USD |
| CY2013 | irwd |
Adjustment To Additional Paid In Capital Vesting Of Restricted Stock No Longer Subject To Repurchase
AdjustmentToAdditionalPaidInCapitalVestingOfRestrictedStockNoLongerSubjectToRepurchase
|
1000 | USD |
| CY2013 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
0 | USD |
| CY2013 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
| CY2012 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
| CY2013Q4 | irwd |
Long Term Purchase Commitment Amount After Fifth Full Fiscal Year
LongTermPurchaseCommitmentAmountAfterFifthFullFiscalYear
|
5000000 | USD |
| CY2012Q4 | irwd |
Proceeds From Grants Received
ProceedsFromGrantsReceived
|
1700000 | USD |
